Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BlossomHill Therapeutics, Inc.BLSM · Entity 5423 | Director · President and CEO · 10% owner | August 06, 2026 | August 10, 2026 |
| Turning Point Therapeutics, Inc.TPTX · Entity 124461 | Director | June 09, 2020 | June 10, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BlossomHill Therapeutics, Inc.
Report date August 06, 2026 · Filed August 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy The Li and Cui Family Trust | 1,714,117 |
Last balance in matching sequence
After 2026-08-10 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-08-10 · Conversion · Acquired 1,600,682 · Balance 1,600,682 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust. Row 2 · 2026-08-10 · Conversion · Acquired 113,435 · Balance 1,714,117 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy RongShan, LLC | 124,779 |
Reported balance
After 2026-08-10 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-08-10 · Conversion · Acquired 124,779 · Balance 124,779 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F3: The Reporting Person's spouse is the manager of RongShan, LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-08-05 | Direct | 676,205 |
Reported balance
After 2026-08-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-06 · Grant · Acquired 676,205 · Balance 676,205 F4: 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months. |
| Series Angel Preferred StockSEC Table II · derivative / convertible security | IndirectBy The Li and Cui Family Trust | 0 |
Reported balance
After 2026-08-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-10 · Conversion · Disposed 1,600,682 · Balance 0 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy The Li and Cui Family Trust | 0 |
Reported balance
After 2026-08-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-10 · Conversion · Disposed 113,435 · Balance 0 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy RongShan, LLC | 0 |
Reported balance
After 2026-08-10 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-10 · Conversion · Disposed 124,779 · Balance 0 F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F3: The Reporting Person's spouse is the manager of RongShan, LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 1,067,121 |
Reported balance
Holding disclosure · report date 2026-08-06 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,067,121 |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 1,067,121 |
Reported balance
Holding disclosure · report date 2026-08-06 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,067,121 |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series Angel Preferred Stock and Series B Preferred Stock (together, the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
F2: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of The Li and Cui Family Trust (the "Trust") and have voting and dispositive power over the securities held by the Trust.
F3: The Reporting Person's spouse is the manager of RongShan, LLC. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F4: 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months.
Turning Point Therapeutics, Inc.
Report date June 09, 2020 · Filed June 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 549,471 |
Reported balance
After 2020-06-09 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2020-06-09 · Sale · Disposed 412 · Balance 549,471 F1: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F2: The weighted average sale price for the transaction reported was $63.80, and the range of prices were between $63.25 and $64.20. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 547,783 |
Reported balance
After 2020-06-09 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2020-06-09 · Sale · Disposed 1,688 · Balance 547,783 F1: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F3: The weighted average sale price for the transaction reported was $64.82, and the range of prices were between $64.26 and $65.17. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 543,268 |
Reported balance
After 2020-06-09 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2020-06-09 · Sale · Disposed 4,515 · Balance 543,268 F1: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F4: The weighted average sale price for the transaction reported was $65.80, and the range of prices were between $65.26 and $66.24. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 540,683 |
Reported balance
After 2020-06-09 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2020-06-09 · Sale · Disposed 2,585 · Balance 540,683 F1: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F5: The weighted average sale price for the transaction reported was $66.60, and the range of prices were between $66.27 and $67.18. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 540,383 |
Reported balance
After 2020-06-09 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2020-06-09 · Sale · Disposed 300 · Balance 540,383 F1: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F6: The weighted average sale price for the transaction reported was $67.48, and the range of prices were between $67.34 and $67.915. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| Common StockSEC Table I · non-derivative | Direct | 1,001,298 |
Reported balance
Holding disclosure · report date 2020-06-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,001,298 |
| Common StockSEC Table I · non-derivative | IndirectBy The Jean Cui 2020 GRAT | 300,000 |
Reported balance
Holding disclosure · report date 2020-06-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 300,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li.
F2: The weighted average sale price for the transaction reported was $63.80, and the range of prices were between $63.25 and $64.20. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3: The weighted average sale price for the transaction reported was $64.82, and the range of prices were between $64.26 and $65.17. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F4: The weighted average sale price for the transaction reported was $65.80, and the range of prices were between $65.26 and $66.24. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F5: The weighted average sale price for the transaction reported was $66.60, and the range of prices were between $66.27 and $67.18. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F6: The weighted average sale price for the transaction reported was $67.48, and the range of prices were between $67.34 and $67.915. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 24, 2020 Filed Apr 24, 2020 20:20 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 3,213 | $50.60 | $162,577.80 |
DisclosureSEC source: 0001209191-20-025731 · doc4.xml · nonDerivative · entry 9 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 697,170 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F8 · price: The weighted average sale price for the transaction reported was $50.60, and the range of prices were between $49.92 and $50.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 20:20 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 400 | $53.82 | $21,528.00 |
DisclosureSEC source: 0001209191-20-025731 · doc4.xml · nonDerivative · entry 8 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 700,383 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F7 · price: The weighted average sale price for the transaction reported was $53.82, and the range of prices were between $53.78 and $53.89. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 20:20 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,200 | $53.22 | $63,864.00 |
DisclosureSEC source: 0001209191-20-025731 · doc4.xml · nonDerivative · entry 7 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 700,783 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F6 · price: The weighted average sale price for the transaction reported was $53.22, and the range of prices were between $52.75 and $53.70. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 20:20 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 2,200 | $52.16 | $114,752.00 |
DisclosureSEC source: 0001209191-20-025731 · doc4.xml · nonDerivative · entry 6 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 701,983 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F5 · price: The weighted average sale price for the transaction reported was $52.16, and the range of prices were between $51.660 and $52.520. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 20:20 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 3,200 | $51.02 | $163,264.00 |
DisclosureSEC source: 0001209191-20-025731 · doc4.xml · nonDerivative · entry 5 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 704,183 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F4 · price: The weighted average sale price for the transaction reported was $51.02, and the range of prices were between $50.530 and $51.480. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 20:20 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,300 | $52.41 | $68,133.00 |
DisclosureSEC source: 0001209191-20-025731 · doc4.xml · nonDerivative · entry 4 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 707,383 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F3 · price: The weighted average sale price for the transaction reported was $52.41, and the range of prices were between $52.11 and $52.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 20:20 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 5,700 | $51.64 | $294,348.00 |
DisclosureSEC source: 0001209191-20-025731 · doc4.xml · nonDerivative · entry 3 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 708,683 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F2 · price: The weighted average sale price for the transaction reported was $51.64, and the range of prices were between $51.09 and $52.08. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 19:16 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 308 | $51.22 | $15,775.76 |
DisclosureSEC source: 0001209191-20-024250 · doc4.xml · nonDerivative · entry 8 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 714,383 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F7 · price: The weighted average sale price for the transaction reported was $51.22, and the range of prices were between $51.135 and $51.3275. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 19:16 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 200 | $49.87 | $9,974.00 |
DisclosureSEC source: 0001209191-20-024250 · doc4.xml · nonDerivative · entry 7 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 714,691 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F6 · price: The weighted average sale price for the transaction reported was $49.87, and the range of prices were between $49.65 and $50.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 13, 2020 Filed Apr 13, 2020 19:16 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 200 | $48.44 | $9,688.00 |
DisclosureSEC source: 0001209191-20-024250 · doc4.xml · nonDerivative · entry 6 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 714,891 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F5 · price: The weighted average sale price for the transaction reported was $48.44, and the range of prices were between $48.405 and $48.48. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 19:16 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,892 | $48.75 | $92,235.00 |
DisclosureSEC source: 0001209191-20-024250 · doc4.xml · nonDerivative · entry 5 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 715,091 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F4 · price: The weighted average sale price for the transaction reported was $48.75, and the range of prices were between $48.35 and $49.145. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 19:16 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 3,626 | $47.82 | $173,395.32 |
DisclosureSEC source: 0001209191-20-024250 · doc4.xml · nonDerivative · entry 4 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 716,983 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F3 · price: The weighted average sale price for the transaction reported was $47.82, and the range of prices were between $47.32 and $48.29. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 19:16 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 5,982 | $46.81 | $280,017.42 |
DisclosureSEC source: 0001209191-20-024250 · doc4.xml · nonDerivative · entry 3 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 720,609 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F2 · price: The weighted average sale price for the transaction reported was $46.81, and the range of prices were between $46.31 and $47.275. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 08, 2020 Filed Apr 8, 2020 19:21 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 100 | $47.23 | $4,722.50 |
DisclosureSEC source: 0001209191-20-023971 · doc4.xml · nonDerivative · entry 13 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 726,591 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. Read SEC document |
| April 08, 2020 Filed Apr 8, 2020 19:21 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 12,106 | $46.43 | $562,081.58 |
DisclosureSEC source: 0001209191-20-023971 · doc4.xml · nonDerivative · entry 12 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 726,691 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F11 · price: The weighted average sale price for the transaction reported was $46.43, and the range of prices were between $46.13 and $47.06. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 08, 2020 Filed Apr 8, 2020 19:21 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 6,294 | $45.89 | $288,800.19 |
DisclosureSEC source: 0001209191-20-023971 · doc4.xml · nonDerivative · entry 11 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 738,797 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F10 · price: The weighted average sale price for the transaction reported was $45.885, and the range of prices were between $45.13 and $46.125. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 19:21 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 5,900 | $45.63 | $269,217.00 |
DisclosureSEC source: 0001209191-20-023971 · doc4.xml · nonDerivative · entry 10 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 745,091 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F9 · price: The weighted average sale price for the transaction reported was $45.63, and the range of prices were between $45.32 and $46.235. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 19:21 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 8,100 | $44.96 | $364,176.00 |
DisclosureSEC source: 0001209191-20-023971 · doc4.xml · nonDerivative · entry 9 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 750,991 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F8 · price: The weighted average sale price for the transaction reported was $44.96, and the range of prices were between $44.32 and $45.27. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 19:21 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 4,500 | $43.69 | $196,605.00 |
DisclosureSEC source: 0001209191-20-023971 · doc4.xml · nonDerivative · entry 8 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 759,091 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F7 · price: The weighted average sale price for the transaction reported was $43.69, and the range of prices were between $43.21 and $44.16. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 19:21 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 300 | $45.13 | $13,539.00 |
DisclosureSEC source: 0001209191-20-023971 · doc4.xml · nonDerivative · entry 7 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 763,591 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F6 · price: The weighted average sale price for the transaction reported was $45.13, and the range of prices were between $45.09 and $45.15. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 19:21 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 2,890 | $44.22 | $127,795.80 |
DisclosureSEC source: 0001209191-20-023971 · doc4.xml · nonDerivative · entry 6 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 763,891 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F5 · price: The weighted average sale price for the transaction reported was $44.22, and the range of prices were between $44.09 and $44.505. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 19:21 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 11,212 | $43.72 | $490,188.64 |
DisclosureSEC source: 0001209191-20-023971 · doc4.xml · nonDerivative · entry 5 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 766,781 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F4 · price: The weighted average sale price for the transaction reported was $43.72, and the range of prices were between $43.085 and $44.08. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 19:21 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 2,998 | $42.61 | $127,744.78 |
DisclosureSEC source: 0001209191-20-023971 · doc4.xml · nonDerivative · entry 4 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 777,993 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F3 · price: The weighted average sale price for the transaction reported was $42.61, and the range of prices were between $42.08 and $43.04. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 19:21 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,100 | $41.46 | $45,606.00 |
DisclosureSEC source: 0001209191-20-023971 · doc4.xml · nonDerivative · entry 3 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 780,991 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F2 · price: The weighted average sale price for the transaction reported was $41.46, and the range of prices were between $40.96 and $41.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 26, 2020 Filed Mar 27, 2020 18:27 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 200 | $48.06 | $9,612.00 |
DisclosureSEC source: 0001209191-20-021490 · doc4.xml · nonDerivative · entry 6 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 782,091 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. Read SEC document |
| March 26, 2020 Filed Mar 27, 2020 18:27 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,648 | $47.48 | $78,247.04 |
DisclosureSEC source: 0001209191-20-021490 · doc4.xml · nonDerivative · entry 5 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 782,291 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F4 · price: The weighted average sale price for the transaction reported was $47.48, and the range of prices were between $47.06 and $47.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 26, 2020 Filed Mar 27, 2020 18:27 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 3,052 | $46.55 | $142,070.60 |
DisclosureSEC source: 0001209191-20-021490 · doc4.xml · nonDerivative · entry 4 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 783,939 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F3 · price: The weighted average sale price for the transaction reported was $46.55, and the range of prices were between $46.04 and $47.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 26, 2020 Filed Mar 27, 2020 18:27 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 6,600 | $45.37 | $299,442.00 |
DisclosureSEC source: 0001209191-20-021490 · doc4.xml · nonDerivative · entry 3 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 786,991 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F2 · price: The weighted average sale price for the transaction reported was $45.37, and the range of prices were between $45.02 and $46.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 25, 2020 Filed Mar 25, 2020 18:47 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 200 | $47.11 | $9,422.00 |
DisclosureSEC source: 0001209191-20-021178 · doc4.xml · nonDerivative · entry 14 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 793,591 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F13 · price: The weighted average sale price for the transaction reported was $47.11, and the range of prices were between $47.105 and $47.11. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 25, 2020 Filed Mar 25, 2020 18:47 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 2,200 | $46.50 | $102,300.00 |
DisclosureSEC source: 0001209191-20-021178 · doc4.xml · nonDerivative · entry 13 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 793,791 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F12 · price: The weighted average sale price for the transaction reported was $46.50, and the range of prices were between $46.09 and $47.005. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 25, 2020 Filed Mar 25, 2020 18:47 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 13,292 | $45.35 | $602,792.20 |
DisclosureSEC source: 0001209191-20-021178 · doc4.xml · nonDerivative · entry 12 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 795,991 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F11 · price: The weighted average sale price for the transaction reported was $45.35, and the range of prices were between $44.97 and $45.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 25, 2020 Filed Mar 25, 2020 18:47 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 2,100 | $44.56 | $93,576.00 |
DisclosureSEC source: 0001209191-20-021178 · doc4.xml · nonDerivative · entry 11 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 809,283 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F10 · price: The weighted average sale price for the transaction reported was $44.56, and the range of prices were between $43.97 and $44.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 24, 2020 Filed Mar 25, 2020 18:47 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 400 | $43.58 | $17,432.00 |
DisclosureSEC source: 0001209191-20-021178 · doc4.xml · nonDerivative · entry 10 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 811,383 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F9 · price: The weighted average sale price for the transaction reported was $43.58, and the range of prices were between $43.345 and $43.88. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 24, 2020 Filed Mar 25, 2020 18:47 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 2,100 | $42.72 | $89,712.00 |
DisclosureSEC source: 0001209191-20-021178 · doc4.xml · nonDerivative · entry 9 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 811,783 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F8 · price: The weighted average sale price for the transaction reported was $42.72, and the range of prices were between $42.30 and $43.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 24, 2020 Filed Mar 25, 2020 18:47 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 3,200 | $41.73 | $133,536.00 |
DisclosureSEC source: 0001209191-20-021178 · doc4.xml · nonDerivative · entry 8 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 813,883 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F7 · price: The weighted average sale price for the transaction reported was $41.73, and the range of prices were between $41.30 and $42.240. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 24, 2020 Filed Mar 25, 2020 18:47 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,300 | $40.75 | $52,975.00 |
DisclosureSEC source: 0001209191-20-021178 · doc4.xml · nonDerivative · entry 7 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 817,083 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F6 · price: The weighted average sale price for the transaction reported was $40.75, and the range of prices were between $40.30 and $41.280. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 18:47 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,200 | $39.63 | $47,556.00 |
DisclosureSEC source: 0001209191-20-021178 · doc4.xml · nonDerivative · entry 6 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 818,383 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F5 · price: The weighted average sale price for the transaction reported was $39.63, and the range of prices were between $39.38 and $39.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 18:47 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 3,000 | $38.77 | $116,310.00 |
DisclosureSEC source: 0001209191-20-021178 · doc4.xml · nonDerivative · entry 5 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 819,583 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F4 · price: The weighted average sale price for the transaction reported was $38.77, and the range of prices were between $38.37 and $39.235. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 18:47 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,900 | $37.88 | $71,972.00 |
DisclosureSEC source: 0001209191-20-021178 · doc4.xml · nonDerivative · entry 4 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 822,583 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F3 · price: The weighted average sale price for the transaction reported was $37.88, and the range of prices were between $37.35 and $38.29. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 18:47 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 900 | $36.52 | $32,868.00 |
DisclosureSEC source: 0001209191-20-021178 · doc4.xml · nonDerivative · entry 3 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 824,483 F1 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F2 · price: The weighted average sale price for the transaction reported was $36.52, and the range of prices were between $36.225 and $36.70. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 12, 2020 Filed Mar 12, 2020 20:40 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 701 | $37.91 | $26,574.91 |
DisclosureSEC source: 0001209191-20-018656 · doc4.xml · nonDerivative · entry 14 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 825,383 F2 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F14 · price: The weighted average sale price for the transaction reported was $37.91, and the range of prices were between $37.480 and $38.385. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 12, 2020 Filed Mar 12, 2020 20:40 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,878 | $36.94 | $69,373.32 |
DisclosureSEC source: 0001209191-20-018656 · doc4.xml · nonDerivative · entry 13 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 826,084 F2 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F13 · price: The weighted average sale price for the transaction reported was $36.94, and the range of prices were between $36.475 and $37.470. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 12, 2020 Filed Mar 12, 2020 20:40 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,821 | $36.07 | $65,683.47 |
DisclosureSEC source: 0001209191-20-018656 · doc4.xml · nonDerivative · entry 12 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 827,962 F2 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F12 · price: The weighted average sale price for the transaction reported was $36.07, and the range of prices were between $35.460 and $36.450. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 12, 2020 Filed Mar 12, 2020 20:40 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 2,600 | $34.96 | $90,896.00 |
DisclosureSEC source: 0001209191-20-018656 · doc4.xml · nonDerivative · entry 11 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 829,783 F2 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F11 · price: The weighted average sale price for the transaction reported was $34.96, and the range of prices were between $34.450 and $35.410. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 20:40 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,400 | $43.72 | $61,208.00 |
DisclosureSEC source: 0001209191-20-018656 · doc4.xml · nonDerivative · entry 10 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 832,383 F2 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F10 · price: The weighted average sale price for the transaction reported was $43.72, and the range of prices were between $43.390 and $44.30. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 20:40 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 3,200 | $42.86 | $137,152.00 |
DisclosureSEC source: 0001209191-20-018656 · doc4.xml · nonDerivative · entry 9 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 833,783 F2 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F9 · price: The weighted average sale price for the transaction reported was $42.86, and the range of prices were between $42.375 and $43.370. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 20:40 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 2,400 | $41.50 | $99,600.00 |
DisclosureSEC source: 0001209191-20-018656 · doc4.xml · nonDerivative · entry 8 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 836,983 F2 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F8 · price: The weighted average sale price for the transaction reported was $41.50, and the range of prices were between $41.290 and $42.120. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 20:40 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 6,800 | $40.61 | $276,148.00 |
DisclosureSEC source: 0001209191-20-018656 · doc4.xml · nonDerivative · entry 7 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 839,383 F2 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F7 · price: The weighted average sale price for the transaction reported was $40.61, and the range of prices were between $40.290 and $41.280. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 20:40 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 4,700 | $40.02 | $188,094.00 |
DisclosureSEC source: 0001209191-20-018656 · doc4.xml · nonDerivative · entry 6 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 846,183 F2 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F6 · price: The weighted average sale price for the transaction reported was $40.02, and the range of prices were between $39.280 and $40.270. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:40 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 3,400 | $43.33 | $147,322.00 |
DisclosureSEC source: 0001209191-20-018656 · doc4.xml · nonDerivative · entry 5 Cui Jingrong Jean · CIK 0001772259 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 850,883 F2 · kind: Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. F5 · price: The weighted average sale price for the transaction reported was $43.33, and the range of prices were between $43.03 and $44.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.